Cybin (HELP) Net Cash Flow (2020 - 2026)
Cybin's (HELP) quarterly Net Cash Flow came in at -$37.8 million in Q1 2026, down 4358.43% YoY from $887251.5 in Q1 2025, and down 133.91% on a QoQ basis from $111.4 million in Q4 2025.
Cybin (HELP) Net Cash Flow (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Net Cash Flow data on file, last reported at -$37.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 4358.43% year-over-year to -$37.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.6 million (up 205.44% YoY) and the FY2026 annual result came in at $63.6 million, up 206.67% from the prior year.
- Net Cash Flow retreated to -$37.8 million in Q1 2026, from $111.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $126.1 million in Q1 2024 to a low of -$37.8 million in Q1 2026.
- A 5-year average of $9.0 million and a median of -$5.4 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow surged 663.81% — and 2026, when it slumped 4358.43%.
- Tracing HELP's Net Cash Flow over 5 years: stood at -$5.5 million in 2022, then surged by 380.59% to $15.5 million in 2023, then plunged by 227.14% to -$19.8 million in 2024, then surged by 663.81% to $111.4 million in 2025, then sank by 133.91% to -$37.8 million in 2026.
- The last three Net Cash Flow figures came in at -$37.8 million (Q1 2026), $111.4 million (Q4 2025), and -$34.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | -37.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.78 Mn |
| Mar 31, 2026 | -37.78 Mn |
| Dec 31, 2025 | 111.42 Mn |
| Dec 31, 2025 | 111.42 Mn |
| Sep 30, 2025 | -34.89 Mn |
| Sep 30, 2025 | -34.89 Mn |
| Jun 30, 2025 | 24.86 Mn |
| Jun 30, 2025 | 24.86 Mn |
| Mar 31, 2025 | -847,450.43 |
| Mar 31, 2025 | -847,450.43 |
| Dec 31, 2024 | -19.76 Mn |
| Dec 31, 2024 | -19.76 Mn |
| Sep 30, 2024 | -19.47 Mn |
| Sep 30, 2024 | -19.47 Mn |
| Jun 30, 2024 | -20.24 Mn |
| Jun 30, 2024 | -20.24 Mn |
| Mar 31, 2024 | 126.11 Mn |
| Mar 31, 2024 | 126.11 Mn |
| Dec 31, 2023 | 15.54 Mn |
| Dec 31, 2023 | 15.54 Mn |